Phaseline

Companies › Shenzhen Ionova Life Sciences

Shenzhen Ionova Life Sciences: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
INV-1120
Selective small molecule for solid malignancies
–Phase 1CancerDec 2026
INV-9956–Phase 1Advanced Metastatic Castration Resistant Prostate CancerJan 2028
INV-6452–Phase 1Breast Cancer (Locally Advanced or Metastatic)Feb 2028
INV-8989
KRAS G12D inhibitor
KRASPhase 1Advance Solid TumorsMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04443088INV-1120Phase 1CancerOncologyDec 2026
NCT06609005INV-9956Phase 1Advanced Metastatic Castration Resistant Prostate CancerOncologyJan 2028
NCT07612891INV-6452Phase 1Breast Cancer (Locally Advanced or Metastatic)OncologyFeb 2028
NCT07610798INV-8989Phase 1Advance Solid TumorsOncologyMay 2029

Targets

KRAS (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.